AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Maple Syrup Urine Disease

Recent research efforts aimed at curing Maple Syrup Urine Disease.

Last updated

Maple Syrup Urine Disease

Overview

Maple Syrup Urine Disease (MSUD) is a rare inherited metabolic condition in which the body cannot adequately break down the branched-chain amino acids leucine, isoleucine, and valine. Harmful buildup of leucine and related ketoacids can cause poor feeding, lethargy, seizures, brain swelling, coma, and death in untreated infants with the severe “classic” form; milder intermediate and intermittent forms can present later or during illness. MSUD is usually caused by disease-causing changes in both copies of BCKDHA, BCKDHB, or DBT, which encode parts of the branched-chain ketoacid dehydrogenase enzyme complex. GeneReviews: Maple Syrup Urine Disease (ncbi.nlm.nih.gov)

Current care aims to prevent toxic leucine elevations through lifelong restriction of dietary branched-chain amino acids, specialized medical formula, valine and isoleucine supplementation when needed, frequent blood monitoring, and rapid high-calorie treatment during illness or metabolic crisis. Liver transplantation can provide enough enzyme activity to permit an unrestricted diet and prevent most metabolic crises, but it is major surgery requiring lifelong immunosuppression and cannot reverse brain injury that occurred before transplantation. GeneReviews: Maple Syrup Urine Disease Liver transplantation review (ncbi.nlm.nih.gov)

Scope of Recent Research (2020–present)

Recent MSUD research has become more active and increasingly focused on one-time gene replacement with adeno-associated virus (AAV) vectors, especially approaches that restore enzyme activity in liver, muscle, heart, and brain rather than liver alone. The field has also pursued gut-restricted oral enzyme therapies that lower absorbed leucine and improved dietary products, but these are disease-modifying rather than curative. A durable molecular cure has not yet entered human clinical testing; however, strong rescue in several mouse models and in a calf makes AAV gene replacement the leading curative research strategy. Neonatal AAV8 gene therapy Dual-gene AAV9 therapy Oral enzyme therapy (pmc.ncbi.nlm.nih.gov)

Major Breakthroughs and Emerging Therapies

The most consequential advance is systemic dual-gene replacement for the two most common genetic forms of classic MSUD, types 1A and 1B. In 2025, researchers developed an AAV9 vector carrying codon-optimized human BCKDHA and BCKDHB genes. A single postnatal dose prevented early death, restored growth and branched-chain ketoacid dehydrogenase activity, and stabilized biochemical markers during high-protein feeding in Bckdha-deficient mice, Bckdhb-deficient mice, and a newborn calf with classic MSUD. The calf remained healthy on an unrestricted, protein-rich diet for more than two years after treatment, an especially important large-animal proof of concept. Dual-gene AAV9 therapy (pubmed.ncbi.nlm.nih.gov)

AAV gene replacement has also shown that broad tissue delivery may be more effective than liver-only treatment. A 2022 study used AAV8 to deliver BCKDHA to newborn Bckdha-knockout mice; a broadly active promoter produced long-term survival, normal growth, and correction of biochemical abnormalities, whereas liver-restricted expression gave only partial rescue. These results are biologically plausible because branched-chain amino-acid metabolism occurs substantially outside the liver, including in muscle and other tissues. Neonatal AAV8 gene therapy (pmc.ncbi.nlm.nih.gov)

A complementary 2021 study targeted the DBT form of MSUD in intermediate-disease mice. Liver-only AAV expression was insufficient, and muscle-only treatment was incomplete; in contrast, AAV9 delivery designed to express the missing DBT gene in both muscle and liver substantially improved survival, maintained near-normal circulating branched-chain amino acids at effective doses, and protected mice from a lethal high-protein challenge. Muscle-directed AAV therapy (sciencedirect.com)

In 2026, the dual-gene AAV9 strategy was further tested with paired blood-and-brain metabolomics in Bckdha-deficient mice. One intravenous dose rescued fatal encephalopathy and restored key brain neurochemical measures to the wild-type range even though some circulating ketoacids remained elevated. This finding strengthens the case for vectors that reach the central nervous system and cautions that blood leucine or ketoacid levels alone may not fully capture treatment of the brain. Brain-metabolomics dual-gene study (sciencedirect.com)

A non-curative but potentially important alternative is oral enzyme therapy. Codexis researchers engineered a leucine decarboxylase, LDCv10, to survive gastric and intestinal conditions and degrade leucine inside the gastrointestinal tract before absorption. In intermediate-MSUD mice and healthy nonhuman primates given protein meals, oral LDCv10 reduced post-meal plasma leucine and ketoisocaproate and was associated with lower brain leucine in mice. Oral enzyme therapy (onlinelibrary.wiley.com)

Clinical Trials and Experimental Approaches

As of August 8, 2026, the published AAV gene-replacement studies for MSUD remain preclinical; their reported efficacy comes from cell, mouse, and calf models rather than treated patients. The leading candidate is the AAV9 dual-BCKDHA/BCKDHB program from investigators at the University of Massachusetts Chan Medical School and the Clinic for Special Children, which is directed at MSUD types 1A and 1B. Dual-gene AAV9 therapy (pubmed.ncbi.nlm.nih.gov)

The recent registered human study most directly related to MSUD treatment is not a curative trial: NCT06581991 evaluated ready-to-use liquid valine and isoleucine supplements in five children, sponsored by Meta Healthcare Ltd. A 2026 report found that the products were well tolerated and easier to use; required supplement doses decreased during the short study, but the small, uncontrolled trial did not test correction of the underlying enzyme defect. NCT06581991 trial record Liquid supplement study (clinicaltrials.gov)

Earlier pharmacologic work with sodium phenylbutyrate also remains exploratory rather than curative. In a completed randomized crossover study of 20 participants, phenylbutyrate did not demonstrate lower 24-hour leucine exposure than placebo in the posted results and was associated with frequent non-serious gastrointestinal symptoms. Phenylbutyrate trial results (clinicaltrials.gov)

Methodologies and Scientific Approaches

MSUD cure research relies on genetically defined disease models that match the major human subtypes, including Bckdha-, Bckdhb-, and Dbt-deficient mice, along with cultured human cells and a naturally affected calf. Researchers compare tissue-specific and broad-expression promoters, AAV8 versus AAV9 capsids, single-gene versus dual-gene payloads, vector dose, survival, growth, tolerance of dietary protein, and restoration of enzyme activity. Neonatal AAV8 gene therapy Dual-gene AAV9 therapy Muscle-directed AAV therapy (pmc.ncbi.nlm.nih.gov)

Key biomarkers include plasma leucine, alloisoleucine, valine, isoleucine, branched-chain ketoacids, and measures of enzyme activity. Newer work adds paired serum-and-brain metabolomics to determine whether a treatment corrects the central nervous system rather than only improving blood chemistry. Brain-metabolomics dual-gene study (sciencedirect.com)

Leading Institutions and Funding

The principal AAV-gene-therapy network includes the University of Massachusetts Chan Medical School, the Clinic for Special Children in Pennsylvania, the University of Texas Southwestern Medical Center, Tufts University, and veterinary collaborators involved in the calf model. The 2025 dual-gene study was led by Jiaming Wang, Kevin A. Strauss, Dan Wang, Guangping Gao, and collaborators across these institutions. Dual-gene AAV9 therapy Research-institution listing (pubmed.ncbi.nlm.nih.gov)

Industry-backed enzyme replacement research is also emerging. In 2025, Syntis Bio received a U.S. National Institutes of Health Small Business Innovation Research award of $343,635 for development of SYNT-213, a once-daily, gut-restricted oral leucine-lowering treatment combining a synthetic intestinal lining platform with a protease-stable leucine decarboxylase. NIH SBIR award for SYNT-213 (sbir.gov)

Strengths, Limitations, and Challenges

The strongest evidence for a future cure is that AAV-based replacement has rescued severe MSUD across multiple genetic mouse models and, notably, in a calf—an unusually informative large-animal model for a rare metabolic disease. The dual-gene design also offers a practical way to treat either BCKDHA- or BCKDHB-related disease with one vector, while systemic delivery may address the muscle and brain components that liver-directed approaches can miss. Dual-gene AAV9 therapy Brain-metabolomics dual-gene study (pubmed.ncbi.nlm.nih.gov)

The major uncertainties are translation, safety, and durability in children. Effective neonatal AAV doses in mice have been high, liver growth can dilute non-integrating AAV genomes over time, and antibodies generated after AAV dosing can make redosing difficult. The current dual-gene program does not directly address DBT-related MSUD, and animal survival or blood biomarker improvements do not yet establish long-term human neurocognitive benefit. Neonatal AAV8 gene therapy Muscle-directed AAV therapy (pmc.ncbi.nlm.nih.gov)

Outlook and Future Directions

MSUD is closer to a plausible molecular cure than it was in 2020, but it is not yet close to an approved curative therapy. The next decisive milestones are formal toxicology and dose-finding studies for systemic dual-gene AAV vectors, demonstration of durable benefit in additional large animals, a plan for treating infants identified through newborn screening, and initiation of a first-in-human trial that measures metabolic-crisis prevention, dietary freedom, brain biomarkers, and neurodevelopment. In parallel, oral leucine-degrading enzymes may offer a less invasive bridge or adjunct that improves metabolic control while gene therapy advances. Dual-gene AAV9 therapy NIH SBIR award for SYNT-213 (pubmed.ncbi.nlm.nih.gov)

References

Don't see your disease? Request a report